The @WHO Africa Region @WHOAFRO is expected to see the largest % increase in cancer incidence by 2050.
The latest #GLOBOCAN estimates project the number of cases to more than double, rising by 125% compared with 2024 cases.
iarc.who.int/news-events/wh…
IARC, @WHO, & partners, reveal scale of disparities in global #BreastCancer survival with launch of 1st-ever WHO Global Breast Cancer Survival Estimates in @NatureMedicine.
New figures provide global benchmark for monitoring breast cancer outcomes.
iarc.who.int/news-events/gl…
The latest #GLOBOCAN estimates from IARC & @AmericanCancer Society suggest that 1 in 5 people develop cancer during their lifetime.
1 in 9 men & 1 in 13 women die from the disease.
Explore more of the latest data on IARC’s #Globocan platform.
iarc.who.int/news-events/gl…
The latest estimates of global cancer incidence & mortality are now available!
IARC estimates that, in 2024, 20.6 million new cases of cancer were diagnosed & 9.8 million people died of cancer.
The🆕data can be found & explored on IARC’s #Globocan platform
iarc.who.int/news-events/gl…
IARC & @WHO launch the WHO Global Status Report on #Cancer 2026!
The Global Status Report was developed jointly by IARC & WHO to provide the most comprehensive analysis of progress across e.g., political commitment, prevention, & investment in treatment.
iarc.who.int/news-events/wh…
Researchers from IARC & partners provide 1st-of-kind evidence for presence of tobacco-specific nitrosamine mutational signature in human tumours.
Signature may contribute to mutational landscape during development of certain cancers linked to tobacco use.
iarc.who.int/news-events/hu…
An #IARCMonographs📙 Working Group evaluated butyl benzyl phthalate (BBzP), dibutyl phthalate (DBP), & diisononyl phthalate (DINP) as possibly carcinogenic to humans, Group 2B.
iarc.who.int/news-events/ia…
What does that mean?🧵
For BBzP, DBP, & DINP, mechanistic evidence was strong, & the evidence for cancer in animals was either sufficient (BBzP & DINP) or limited (DBP). Evidence for cancer in humans was inadequate .
The Working Group evaluated BBzP, DBP, & DINP as possibly carcinogenic to humans, 2B.
Don't forget, the IARC Monographs classifications indicate strength of evidence that a substance can cause #cancer, not the cancer risk associated with different routes & levels of exposure.
Agents in the same Group can have very different cancer risk.
The results of the #IARCMonographs📙 evaluations of butyl benzyl phthalate (BBzP), dibutyl phthalate (DBP), & diisononyl phthalate (DINP) have been published in @TheLancetOncol.
The Working Group evaluated each as possibly carcinogenic to humans, Group 2B
iarc.who.int/news-events/ia…
The results of the #IARCMonographs📙 evaluation of 3 chemicals (butyl benzyl phthalate (BBzP), dibutyl phthalate (DBP), & diisononyl phthalate (DINP)) have been published in @TheLancetOncol.
The article presents the conclusions of Monographs Meeting 142
iarc.who.int/news-events/ia…
IARC launches new website to support ECCE project
ECCE aims to uncover unknown causes of colorectal cancer, particularly of colorectal cancer in people aged less than 50 years old.
iarc.who.int/news-events/ia…
Le Circ adresse ses plus chaleureuses félicitations à la Dre Suzette Delaloge pour sa nomination à la présidence de l'@Institut_cancer.
Nous nous réjouissons de poursuivre notre collaboration et notre engagement commun au service de la prévention du cancer, en 🇫🇷 et bien au-delà.
🆕paper in @AnnalsofIM compares #LungCancer risk prediction models (RPMs) Vs US criteria used to determine eligibility for lung #cancer screening. All included RPMs achieved better avg estimated efficiency than criteria,&↘️racial/ethnic diffs in efficiency
iarc.who.int/news-events/pe…
IARC’s Initiative for Resilience in #CancerControl held a seminar with Prof Alessandro Jatobá (@fiocruz) & Dr Marco Paschoalotto (@UMinho_Oficial) on health system resilience & cancer control, & a collab workshop, a 1st event under the🆕IARC–Fiocruz MoU. iarc.who.int/news-events/ia…
Happening now at #ASCOBT26: We’re diving into the global rise of early-onset cancers. Experts are discussing modifiable risk factors and emerging genomic data specific to the Asia-Pacific region. 🌏
